Alport Syndrome Treatment Market Size Worth $19.00 Million By 2032 | CAGR: 4.5%

Alport Syndrome Treatment Market Size Worth $19.00 Million By 2032 | CAGR: 4.5%

The global alport syndrome treatment market size is expected to reach USD 19.00 million by 2032, according to a new study by Polaris Market Research. The report “Alport Syndrome Treatment Market Share, Size, Trends, Industry Analysis Report, By Product Type; By Disease Type; By Route Of Administration; By Distribution Channel (Online and  Offline); By End User; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides an analysis of future market growth.

Market growth is primarily due to the increasing number of clinical studies for treating Alport syndromes. For instance, in February 2023, the first participants in the Phase 2 research of ELX-02 to treat Alport syndrome in patients with non-sense mutations have now been enrolled, as per the statement of Eloxx Pharmaceuticals. Around 8 Alport syndrome patients with non-sense mutations in the COL4 gene will be treated in this Phase 2 trial. Patients will receive two months of medication, followed by a three-month checkup.

Furthermore, the market is expanding due to rising technical developments in treating Alport syndrome. For instance, in July 2021, Bardoxolone methyl (RTA 402) was submitted as an NDA by Kyowa Kirin for the treatment of Alport Syndrome. The effectiveness and safety information from the CARDINAL Phase 3 clinical study, which Reata carried out for patients with Alport Syndrome, served as the foundation for this application. The firms that make up the Kyowa Kirin Group work to improve people’s health and quality of life worldwide by generating new value by pursuing advancements in life sciences and technology. Therefore, the rising clinical trials for the treatment drive market growth over the forecast period.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below:

Additionally, the market is anticipated to grow significantly due to significant investments made by major companies and government efforts for drug Research & Development (R&D) to treat Alport syndrome and associated symptoms. For instance, in August 2021, on the safety, effectiveness, and tolerability of spartan oral suspension and evaluating changes in proteinuria following once-daily dosage throughout a 108-week treatment period, Travere Therapeutics conducted a Phase II clinical research investigation. As a result, the market is anticipated to develop as diagnostic tests are adopted and made more widely available.

Alport Syndrome Treatment Market Report Highlights

  • The hospital pharmacy segment is anticipated to grow at a high CAGR over the forecast period hospitals are a crucial component of the healthcare business
  • Tablets in the Alport Syndrome Treatment Market are expected to witness significant growth due to convenience, technological advancements, and cost-effectiveness.
  • Asia Pacific holds a dominant market share. This results from the growing number of generic medicine producers and the frequency of renal failure and associated illnesses.
  • The global players include AstraZeneca, Centogene, Eurofins, Roche Ltd., Quest Diagnostics, Ravgen, Sanofi Group, and Teva Pharmaceutical.

Polaris Market Research has segmented the alport syndrome treatment market report based on product type, disease type, route of administration, distribution channel, end-user, and region:

Alport Syndrome Treatment Market, Product Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Tablets
  • Capsules
  • Injectables
  • Others

    Alport Syndrome Treatment Market, Disease Type Outlook (Revenue - USD Million, 2019 - 2032)

  • X-linked Alport Syndrome
  • Autosomal Recessive Alport Syndrome
  • Autosomal Dominant Alport Syndrome

Alport Syndrome Treatment Market, Route Of Administration Outlook (Revenue - USD Million, 2019 - 2032)

  • Oral
  • Parenteral
  • Others

    Alport Syndrome Treatment Market, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

  • Online
  • Offline

Alport Syndrome Treatment Market, End User Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Specialty Clinics

Alport Syndrome Treatment Market, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa